- Home
- TXN vs NVS Comparison
TXN vs NVS Comparison
Compare TXN & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXN | NVS |
|---|---|---|
| Founded | 1930 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.9B | 310.4B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | TXN | NVS |
|---|---|---|
| Price | $191.08 | $154.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 4 |
| Target Price | ★ $217.13 | $118.00 |
| AVG Volume (30 Days) | ★ 5.6M | 2.4M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.86% | 1.99% |
| EPS Growth | ★ 4.81 | N/A |
| EPS | ★ 5.45 | N/A |
| Revenue | ★ $17,682,000,000.00 | N/A |
| Revenue This Year | $11.66 | $2.56 |
| Revenue Next Year | $10.41 | $4.91 |
| P/E Ratio | $36.47 | ★ $23.13 |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $139.95 | $97.72 |
| 52 Week High | $231.32 | $170.46 |
Technical Indicators
Market Signals| Indicator | TXN | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 32.29 | 41.18 |
| Support Level | $174.78 | $113.19 |
| Resistance Level | $192.92 | $158.80 |
| Average True Range (ATR) | 5.24 | 2.42 |
| MACD | -2.85 | -1.89 |
| Stochastic Oscillator | 2.74 | 4.18 |
Price Performance
Historical ComparisonAbout TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.